½ÃÀ庸°í¼­
»óǰÄÚµå
1591780

½ÉÀå ÆÇ¸· ±â±â ½ÃÀå : À¯Çüº°, ÃÖÁ¾ »ç¿ëÀÚº° - ¼¼°è ¿¹Ãø(2025-2030³â)

Heart Valve Devices Market by Type (Biological Heart Valves, Mechanical Heart Valves, Transcatheter Heart Valves), End User (Ambulatory Surgical Centers, Hospitals) - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 185 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

½ÉÀå ÆÇ¸· ±â±â ½ÃÀåÀº 2023³â 79¾ï 6,000¸¸ ´Þ·¯·Î Æò°¡µÇ°í 2024³â¿¡´Â87¾ï 4,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, CAGR 9.90%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 154¾ï 2,000¸¸´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

½ÉÀå ÆÇ¸· ±â±â ½ÃÀå¿¡´Â ÁÖ·Î ½Â¸ðÆÇ¸·, ´ëµ¿¸Æ ÆÇ¸·, Æóµ¿¸Æ ÆÇ¸·, »ï÷ÆÇ¸·À» Áß½ÉÀ¸·Î ½ÉÀåÀÇ ÀÚ¿¬ ÆÇ¸· ±â´ÉÀ» ÀçÇöÇϵµ·Ï ¼³°èµÈ ÀÇ·á±â±â°¡ Æ÷ÇԵ˴ϴÙ. ÀÌ·¯ÇÑ ÀÇ·á±â±â´Â Àα¸ °í·ÉÈ­¿Í »ýȰ ½À°ü °ü·Ã ½ÉÇ÷°ü ÁúȯÀÇ À¯º´·ü Áõ°¡·Î ÀÎÇÑ ½ÉÀå ÆÇ¸· Àå¾Ö ¹ß»ý·ü Áõ°¡·Î ÀÎÇØ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. °áÇÔÀÌ ÀÖ´Â ½ÉÀå ÆÇ¸·À» ±³Ã¼Çϰųª ¼ö¸®ÇÏ´Â ¼ö¼ú ¹× ÃÖ¼Ò Ä§½À ¼ö¼ú¿¡ Àû¿ëµÇ¾î ȯÀÚÀÇ ±â´ë ¼ö¸í°ú ǰÁúÀ» Çâ»ó½Ãŵ´Ï´Ù. ÃÖÁ¾ »ç¿ëÀÚ´Â º´¿ø, ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC), Àü¹® Ŭ¸®´Ð µî ´Ù¾çÇÕ´Ï´Ù. ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ¿øµ¿·ÂÀº °æÇÇÀû Ä«Å×ÅÍ ¹ëºê ±³Ã¼/º¹¿ø ±â¼ú°ú °°Àº ±â¼ú ¹ßÀü, ÀÇ·áºñ ÁöÃâ Áõ°¡, Ȱ¹ßÇÑ ¿¬±¸ °³¹ß ÅõÀÚÀÔ´Ï´Ù. ¼¼°è Àα¸ÀÇ °í·ÉÈ­¿Í ÃÖ¼Ò Ä§½À ¼ö¼úÀÇ ±Þ°ÝÇÑ Áõ°¡´Â ½ÉÀå ÆÇ¸· ÀåÄ¡ÀÇ Ã¤Åà Ȯ´ë¿¡ À¯¸®ÇÑ ±âȸ¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÁÖ¿ä ±â¾÷ °£ÀÇ Àü·«Àû Á¦ÈÞ¿Í ÀμöÇÕº´Àº ±â¼ú Çõ½Å°ú ½ÃÀå È®´ë¸¦ ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±×·¯³ª ¾ö°ÝÇÑ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©, ÀáÀçÀûÀÎ ±â±â °áÇÔ, ³ôÀº ±â±â ºñ¿ë µîÀÇ ¹®Á¦°¡ ¼ºÀåÀ» ÀúÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ¼ö¼ú·Î ÀÎÇÑ ÇÕº´Áõ À§Çè°ú Àü ¼¼°èÀûÀ¸·Î »óÀÌÇÑ »óȯ ½Ã³ª¸®¿À µîÀÌ ÇѰè·Î ÀÛ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Àå¾Ö¹°¿¡µµ ºÒ±¸Çϰí, ¹ëºêÀÇ ¼ö¸í ¿¬ÀåÀ» À§ÇÑ »ýüÀûÇÕ¼º ¼ÒÀç, ȯÀÚ ¸ÂÃãÇü ±â±â ¸ÂÃãÈ­¸¦ À§ÇÑ AIÀÇ ¹ßÀü, ½Ã¼ú °á°ú¸¦ °³¼±ÇÏ´Â °æÇÇÀû Ä«Å×ÅÍ ¹ëºê ±â¼ú °³¹ß µî ±â¼ú Çõ½ÅÀÇ ±âȸ°¡ ¸¹Àº ºÐ¾ß°¡ ÀÖ½À´Ï´Ù. ¹ëºêÀÇ ³»±¸¼º Çâ»ó, ¼ö¼ú ÈÄ ÇÕº´Áõ °¨¼Ò, ÃÖ¼Òħ½ÀÀû ½Ã¼úÀ» À§ÇÑ Àü´Þ ½Ã½ºÅÛ °³¼±¿¡ ÃÊÁ¡À» ¸ÂÃá ¿¬±¸´Â ½ÃÀå ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ½À´Ï´Ù. Ä¡¿­ÇÑ °æÀï°ú ºü¸¥ ±â¼ú ÁøÈ­¸¦ Ư¡À¸·Î ÇÏ´Â ÀÌ ½ÃÀåÀº Á¦Ç° ¶óÀξ÷À» ÅëÇÕÇϰí Áö¸®Àû ¹üÀ§¸¦ È®´ëÇÏ´Â ¹æÇâÀ¸·Î ³ª¾Æ°¡°í ÀÖ½À´Ï´Ù. ½ÃÀå Á¡À¯À²À» È®º¸ÇϰíÀÚ ÇÏ´Â ±â¾÷Àº Àü·«Àû Á¦ÈÞ, ²÷ÀÓ¾ø´Â Çõ½Å, ¼ÒºñÀÚ ÀÎÁöµµ¸¦ ³ôÀ̱â À§ÇÑ Àû±ØÀûÀÎ ¸¶ÄÉÆÃ Àü·«, ÀÇ·á ÀÎÇÁ¶ó°¡ ±¸ÃàµÇ°í ÀÖ´Â ½ÅÈï ½ÃÀå¿¡ ´ëÇÑ ÅõÀÚ¸¦ ¿ì¼±¼øÀ§¿¡ µÎ¾î¾ß ÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁØ ¿¬µµ(2023³â) 79¾ï 6,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2024³â) 87¾ï 4,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2030³â) 154¾ï 2,000¸¸ ´Þ·¯
CAGR(%) 9.90%

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â ½ÉÀå ÆÇ¸· ±â±â ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

½ÉÀå ÆÇ¸· ±â±â ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ º¯È­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤À» ³»¸®°í, Àü·«ÀûÀÎ ÀÇ»ç°áÁ¤À» Á¤±³È­Çϸç, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ®·»µå¸¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª Àü¹Ý¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ³ôÀº ÆÇ¸·Áõ ¹ß»ý·ü°ú ÇÔ²² Àü ¼¼°è ³ëÀÎ Àα¸ÀÇ ±Þ°ÝÇÑ Áõ°¡
    • ÆÇ¸·ÁõÀÇ Á¤È®ÇÑ Áø´ÜÀ» À§ÇÑ °í±Þ °è»ê µµ±¸ÀÇ °¡¿ë¼º Áõ´ë
    • ÃÖ¼Òħ½ÀÀû ½Ã¼ú·ÎÀÇ Àüȯ°ú ÀÇ·áºñ ÁöÃâ Áõ°¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • Ä¡·á¿¡ µû¸¥ ÇÕº´Áõ
    • Á¦Á¶ºñ¿ëÀÌ ¸¹ÀÌ µé¾î°¡±â ¶§¹®¿¡ »ó´ëÀûÀ¸·Î °í°¡ÀÇ Àåºñ
  • ½ÃÀå ±âȸ
    • ¹ëºê Ä¿½ºÅ͸¶ÀÌ¡À» ÅëÇÑ ±â¼ú ¹ßÀü
    • ¿ìÈ£ÀûÀÎ »óȯÁ¤Ã¥°ú Á¤ºÎ ¿¬±¸ºñ Áõ°¡
  • ½ÃÀå °úÁ¦
    • º¹ÀâÇÑ ±ÔÁ¦ ÀýÂ÷·Î ÀÎÇÑ Á¦Ç° ½ÂÀÎ ¹®Á¦

Porter's Five Forces : ½ÉÀå ÆÇ¸· ±â±â ½ÃÀåÀ» Ž»öÇÏ´Â Àü·«Àû µµ±¸

"Portre's Five Forces" ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÆÄ¾ÇÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÂû·ÂÀ» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ½ÉÀå ÆÇ¸· ±â±â ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ½ÉÀå ÆÇ¸· ±â±â ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® ½ÉÀå ÆÇ¸· ±â±â ½ÃÀå¿¡¼­°æÀï ±¸µµ ÆÄ¾Ç

½ÉÀå ÆÇ¸· ±â±â ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­, ÅëÇÕÀÇ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÅëÂû·ÂÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º ½ÉÀåÆÇ¸· ÀåÄ¡ ½ÃÀå¿¡¼­°ø±Þ¾÷ü ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ½ÉÀå ÆÇ¸· ±â±â ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î º¥´õ¸¦ Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× Ãßõ ½ÉÀå ÆÇ¸· ±â±â ½ÃÀå¿¡¼­ ¼º°øÀÇ ±æÀ» ±×¸®´Ù.

½ÉÀå ÆÇ¸· ±â±â ½ÃÀå Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ½Äº°ÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ °æÀï ȯ°æÀÇ µµÀüÀ» ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö ÀÖµµ·Ï ÁغñÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸ °³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • PorterÀÇ Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå ½ÉÀå ÆÇ¸· ±â±â ½ÃÀå : À¯Çüº°

  • »ý¹°ÇÐÀû ½ÉÀåÆÇ¸·
    • ´ëµ¿¸ÆÆÇ¸·
    • ½Â¸ðÆÇ
    • Æóµ¿¸ÆÆÇ¸·
    • »ï÷ÆÇ
  • Àΰø½ÉÀåÆÇ¸·
    • ´ëµ¿¸ÆÆÇ¸·
    • ½Â¸ðÆÇ
  • °æÄ«Å×ÅÍ ½ÉÀåÆÇ¸·
    • ´ëµ¿¸ÆÆÇ¸·
    • ½Â¸ðÆÇ
    • Æóµ¿¸ÆÆÇ¸·

Á¦7Àå ½ÉÀå ÆÇ¸· ±â±â ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
  • º´¿ø

Á¦8Àå ¾Æ¸Þ¸®Ä«ÀÇ ½ÉÀå ÆÇ¸· ±â±â ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦9Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½ÉÀå ÆÇ¸· ±â±â ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦102Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ½ÉÀå ÆÇ¸· ±â±â ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦11Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®, 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸®½ºÆ®

  • Abbott Laboratories
  • Boston Scientific Corporation
  • CryoLife, Inc.
  • Edward Lifesciences Corporation
  • JenaValve Technology, Inc.
  • Medtronic
  • Micro Interventional Devices
  • Neovasc, Inc.
  • Sorin Group
  • Symetis SA
LSH

The Heart Valve Devices Market was valued at USD 7.96 billion in 2023, expected to reach USD 8.74 billion in 2024, and is projected to grow at a CAGR of 9.90%, to USD 15.42 billion by 2030.

The heart valve devices market encompasses medical devices designed to replicate the function of the heart's natural valves, primarily focusing on mitral, aortic, pulmonary, and tricuspid valves. These devices are crucial due to rising incidences of heart valve disorders stemming from an aging population and increasing prevalence of lifestyle-related cardiovascular diseases. They are applied in surgical and minimally-invasive procedures to replace or repair faulty heart valves, enhancing patient life expectancy and quality. End-users span across hospitals, ambulatory surgical centers, and specialty clinics. Market growth is significantly driven by technological advancements like transcatheter valve replacement/repair technologies, rising healthcare expenditure, and robust R&D investments. An aging global population and a surge in minimally invasive surgeries are creating lucrative opportunities for increased adoption of heart valve devices. Furthermore, strategic partnerships and acquisitions among key players are anticipated to foster innovation and market expansion. However, challenges such as stringent regulatory frameworks, potential device malfunctions, and high device costs can impede growth. Limitations include the risk of complications from surgical procedures and varying reimbursement scenarios globally. Despite these hurdles, there are numerous areas ripe for innovation such as biocompatible materials for valve longevity, advancements in AI for patient-specific device customization, and developments in transcatheter valve technologies improving procedural outcomes. Research focusing on enhancing valve durability, reducing post-surgical complications, and improving delivery systems for minimally invasive techniques can reinforce market positions. The market, characterized by intense competition and rapid technological evolution, is directed towards consolidating product offerings and expanding geographic reach. Businesses aiming to capture market share should prioritize strategic alliances, continuous innovation, aggressive marketing strategies to enhance consumer awareness, and investments in emerging markets with growing healthcare infrastructures.

KEY MARKET STATISTICS
Base Year [2023] USD 7.96 billion
Estimated Year [2024] USD 8.74 billion
Forecast Year [2030] USD 15.42 billion
CAGR (%) 9.90%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Heart Valve Devices Market

The Heart Valve Devices Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Surge in geriatric population globally coupled with high incidence of valvular diseases
    • Growing availability of advanced computational tools toward accurate diagnosis of valvular disease
    • Shift towards minimal invasive procedures and increasing healthcare expenditure
  • Market Restraints
    • Complications associated to the treatment
    • Relatively expensive device due to extensive manufacturing cost
  • Market Opportunities
    • Technological advancements with customization of valves
    • Favourable reimbursement policies and increased government funding for research
  • Market Challenges
    • Issues with product approval owing to complex regulatory procedures

Porter's Five Forces: A Strategic Tool for Navigating the Heart Valve Devices Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Heart Valve Devices Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Heart Valve Devices Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Heart Valve Devices Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Heart Valve Devices Market

A detailed market share analysis in the Heart Valve Devices Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Heart Valve Devices Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Heart Valve Devices Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Heart Valve Devices Market

A strategic analysis of the Heart Valve Devices Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Heart Valve Devices Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Boston Scientific Corporation, CryoLife, Inc., Edward Lifesciences Corporation, JenaValve Technology, Inc., Medtronic, Micro Interventional Devices, Neovasc, Inc., Sorin Group, and Symetis SA.

Market Segmentation & Coverage

This research report categorizes the Heart Valve Devices Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Biological Heart Valves, Mechanical Heart Valves, and Transcatheter Heart Valves. The Biological Heart Valves is further studied across Aortic Valves, Mitral Valves, Pulmonary Valves, and Tricuspid Valves. The Mechanical Heart Valves is further studied across Aortic Valves and Mitral Valves. The Transcatheter Heart Valves is further studied across Aortic Valves, Mitral Valves, and Pulmonary Valves.
  • Based on End User, market is studied across Ambulatory Surgical Centers and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Surge in geriatric population globally coupled with high incidence of valvular diseases
      • 5.1.1.2. Growing availability of advanced computational tools toward accurate diagnosis of valvular disease
      • 5.1.1.3. Shift towards minimal invasive procedures and increasing healthcare expenditure
    • 5.1.2. Restraints
      • 5.1.2.1. Complications associated to the treatment
      • 5.1.2.2. Relatively expensive device due to extensive manufacturing cost
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements with customization of valves
      • 5.1.3.2. Favourable reimbursement policies and increased government funding for research
    • 5.1.4. Challenges
      • 5.1.4.1. Issues with product approval owing to complex regulatory procedures
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Heart Valve Devices Market, by Type

  • 6.1. Introduction
  • 6.2. Biological Heart Valves
    • 6.2.1. Aortic Valves
    • 6.2.2. Mitral Valves
    • 6.2.3. Pulmonary Valves
    • 6.2.4. Tricuspid Valves
  • 6.3. Mechanical Heart Valves
    • 6.3.1. Aortic Valves
    • 6.3.2. Mitral Valves
  • 6.4. Transcatheter Heart Valves
    • 6.4.1. Aortic Valves
    • 6.4.2. Mitral Valves
    • 6.4.3. Pulmonary Valves

7. Heart Valve Devices Market, by End User

  • 7.1. Introduction
  • 7.2. Ambulatory Surgical Centers
  • 7.3. Hospitals

8. Americas Heart Valve Devices Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Heart Valve Devices Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Heart Valve Devices Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Boston Scientific Corporation
  • 3. CryoLife, Inc.
  • 4. Edward Lifesciences Corporation
  • 5. JenaValve Technology, Inc.
  • 6. Medtronic
  • 7. Micro Interventional Devices
  • 8. Neovasc, Inc.
  • 9. Sorin Group
  • 10. Symetis SA
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦